First-Line HIV Treatment: Research
 SPARTAN: Two-Drug, NRTI-Sparing Strategies Continue to Disappoint (June 8, 2012)
From Journal Watch
On TheBodyPRO.com
- What Lies Ahead: Trends in HIV Treatment and Care (March/April 2012)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
- HIV/AIDS Researcher David Ho Wins NIDA's 2011 Avant-Garde Award (August 12, 2011)
Ho plans to develop a revolutionary, long-acting HIV therapy to improve adherence to treatment.
From U.S. National Institutes of Health
On TheBodyPRO.com
- New Experimental Drug Blocks HIV Infection Early, Scientists Report (December 23, 2010)
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
On TheBodyPRO.com
- Small Study Suggests Once-Daily MVC Plus ATV/r as Viable First Regimen (July 26, 2010)
From National AIDS Treatment Advocacy Project
- Kaletra/Isentress Shows Promise as HIV Nuceleoside-Sparing Regimen for First-Line Treatment (July 20, 2010)
From AIDSmeds.com
- First-Line Lopinavir/r/Raltegravir (With No NRTIs) in Treatment Naive (July 19, 2010)
From National AIDS Treatment Advocacy Project
- Side Effect and CD4 Differences in Four ACTG 5202 Arms at 96 Weeks (February 18, 2010)
From National AIDS Treatment Advocacy Project
- Overweight People With HIV See Lower CD4 Gain While on HIV Medications, Study Suggests (November 19, 2009)
An interview with Nancy Crum-Cianflone, M.D., M.P.H.
In HIV News & Views, from TheBody.com
- HIV Treatment Lagging Behind for Many Infected Youth (May 3, 2009)
Health care providers often decide not to start young HIVers on HIV treatment even though their CD4 count is below 350, a new U.S. study has found.
From Johns Hopkins University
On TheBodyPRO.com
- Starting HIV Therapy May Improve Some Markers of Heart Health, Small Study Finds (April 21, 2009)
These new findings won't necessarily clear up the still-obscure relationship between HIV, HIV meds and heart disease, but they do support the idea that starting HIV treatment may not automatically jack up your cardiovascular risk.
From aidsmap.com
- High Adherence May Become Less Essential the Longer a Patient Maintains Viral Suppression on HAART, Findings Suggest (February 11, 2009)
Maximum adherence should always remain a goal when taking HAART. However, patients with sustained viral suppression on HAART are highly likely to maintain that viral suppression even in the face of adherence rates much lower than 95 percent, reports David Bangsberg, M.D., M.P.H.
In The 16th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- During First 45 Days Post HAART Initiation Patients Hospitalized Most Often for Non-AIDS-Defining Infections (February 9, 2009)
An interview with Stephen Berry, M.D.
In 16th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- People Diagnosed With Extremely Low CD4 Counts Usually Respond Well to Treatment, Study Finds (November 20, 2008)
From aidsmap.com
- First-Line HIV Treatment Regimens Last Longer Than Ever, Study Shows (September 16, 2008)
From aidsmap.com
- Dietary Intervention When Starting HAART Prevents the Increase in Lipids Independently of Drug Regimen: A Randomized Trial (July 25, 2007)
From International AIDS Society
- New Developments in the Management of HIV Treatment-Naive Patients (February 28, 2007)
Includes an analysis of research examining once-daily regimens, the use of viral decay rate to assess treatment efficacy, and issues related to primary HIV drug resistance.
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Emergence of Drug Resistance and First-Line Combination Therapy in the Swiss HIV Cohort Study (February 26, 2007)
To view original study poster, click here (PDF).
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- ACTG 5142 -- Battle of the Titans (February 2007)
A prospective, randomized, phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection -- ACTG 5142.
In HIV JournalView, from TheBodyPRO.com
- Five-Year Study Demonstrates Similar Outcomes for NNRTI-Based and PI-Based Regimens (August 15, 2006)
In The XVI International AIDS Conference
On TheBodyPRO.com
- Study: No Advantage to Adding Fourth Drug to AIDS Cocktail (August 15, 2006)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
On TheBodyPRO.com
|
Advertisement
|
Email
Glossary
